QuidelOrtho Corporation (NASDAQ:QDEL) Receives $12.38 Consensus Target Price from Analysts

Shares of QuidelOrtho Corporation (NASDAQ:QDEL) have earned an average rating of “Reduce” from the six brokerages that are presently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $13.6250.

QDEL has been the subject of several analyst reports. Citigroup raised their price target on shares of QuidelOrtho from $13.00 to $18.00 and gave the company a “neutral” rating in a report on Wednesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of QuidelOrtho in a report on Tuesday, April 21st. Jefferies Financial Group restated a “hold” rating on shares of QuidelOrtho in a research note on Monday, June 29th. Zacks Research raised QuidelOrtho from a “strong sell” rating to a “hold” rating in a research report on Monday, June 15th. Finally, Wall Street Zen raised QuidelOrtho from a “sell” rating to a “hold” rating in a report on Sunday, June 28th.

Institutional Trading of QuidelOrtho

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Aristotle Capital Boston LLC grew its holdings in QuidelOrtho by 62.4% during the 3rd quarter. Aristotle Capital Boston LLC now owns 382,389 shares of the company’s stock worth $11,261,000 after acquiring an additional 146,956 shares in the last quarter. Tejara Capital Ltd raised its stake in shares of QuidelOrtho by 97.2% in the 4th quarter. Tejara Capital Ltd now owns 208,327 shares of the company’s stock valued at $5,950,000 after purchasing an additional 102,700 shares in the last quarter. Phocas Financial Corp. lifted its position in shares of QuidelOrtho by 45.7% during the fourth quarter. Phocas Financial Corp. now owns 170,018 shares of the company’s stock worth $4,856,000 after purchasing an additional 53,353 shares during the last quarter. Rice Hall James & Associates LLC grew its stake in QuidelOrtho by 222.0% in the fourth quarter. Rice Hall James & Associates LLC now owns 833,791 shares of the company’s stock worth $23,813,000 after purchasing an additional 574,877 shares in the last quarter. Finally, Monaco Asset Management SAM increased its holdings in QuidelOrtho by 131.0% in the fourth quarter. Monaco Asset Management SAM now owns 202,595 shares of the company’s stock valued at $5,786,000 after buying an additional 114,895 shares during the last quarter. Institutional investors own 99.00% of the company’s stock.

QuidelOrtho Stock Up 1.5%

Shares of QuidelOrtho stock opened at $17.25 on Friday. QuidelOrtho has a twelve month low of $9.92 and a twelve month high of $35.58. The stock has a market cap of $1.18 billion, a price-to-earnings ratio of -0.97 and a beta of 0.69. The company has a current ratio of 1.43, a quick ratio of 0.80 and a debt-to-equity ratio of 1.33. The company has a fifty day moving average price of $13.40 and a 200 day moving average price of $19.64.

QuidelOrtho (NASDAQ:QDEL) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.41). QuidelOrtho had a positive return on equity of 4.25% and a negative net margin of 45.57%.The company had revenue of $619.80 million for the quarter, compared to analyst estimates of $665.23 million. During the same quarter in the prior year, the firm earned $0.74 EPS. The company’s revenue for the quarter was down 10.5% compared to the same quarter last year. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. Equities research analysts forecast that QuidelOrtho will post 1.87 earnings per share for the current fiscal year.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.